10.24.19
AptarGroup’s Activ-Blister packaging solution for oral solid dose drug delivery was recently approved by the U.S. Food and Drug Administration (FDA) for a HIV prevention medicine.
The oral solid dose drug was developed by a leading pharmaceutical company in the HIV treatment and prevention space, and represents the first FDA approval of Aptar’s Activ-Blister packaging solution and application process developed by Aptar CSP Technologies.
The system protects oral solid drug products with a 3-Phase Activ-Polymer solution that is fully integrated into the blister package. This technology can be customized specifically for the drug developer’s formulation and offers a broad spectrum of specific drug protection including moisture adsorption, and oxygen and odor scavenging. The technology can also scavenge volatile organic compounds (VOCs) and emit aromas.
Aptar’s portfolio of 3-Phase Activ-Polymerprotective solutions helps pharma and biopharma partners meet specific drug long-term and in-use stability requirements while maintaining therapeutic efficacy, as well as a patient-friendly packaging configuration.
“I am very pleased to announce this recent FDA approval of our proprietary Activ-Blister technology,” said Stephan Tanda, Aptar’s president and chief executive officer. “This is a significant step that further validates the expanding portfolio of solutions offered by Aptar CSP Technologies. We will continue to leverage our proprietary 3-Phase Activ-Polymertechnology to help our customers with unique protective formulations that derisk their drug development process and help strengthen their own offerings. The ultimate result is that we are creating meaningful solutions that help improve and save lives.”
Visit Aptar at CPhI booth 111D70.
The oral solid dose drug was developed by a leading pharmaceutical company in the HIV treatment and prevention space, and represents the first FDA approval of Aptar’s Activ-Blister packaging solution and application process developed by Aptar CSP Technologies.
The system protects oral solid drug products with a 3-Phase Activ-Polymer solution that is fully integrated into the blister package. This technology can be customized specifically for the drug developer’s formulation and offers a broad spectrum of specific drug protection including moisture adsorption, and oxygen and odor scavenging. The technology can also scavenge volatile organic compounds (VOCs) and emit aromas.
Aptar’s portfolio of 3-Phase Activ-Polymerprotective solutions helps pharma and biopharma partners meet specific drug long-term and in-use stability requirements while maintaining therapeutic efficacy, as well as a patient-friendly packaging configuration.
“I am very pleased to announce this recent FDA approval of our proprietary Activ-Blister technology,” said Stephan Tanda, Aptar’s president and chief executive officer. “This is a significant step that further validates the expanding portfolio of solutions offered by Aptar CSP Technologies. We will continue to leverage our proprietary 3-Phase Activ-Polymertechnology to help our customers with unique protective formulations that derisk their drug development process and help strengthen their own offerings. The ultimate result is that we are creating meaningful solutions that help improve and save lives.”
Visit Aptar at CPhI booth 111D70.
